[11C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy Export

@article{citeulike:2810207, abstract = {Abstract Purpose\ \ The accuracy of positron emission tomography (PET)/CT with [11C]choline for the detection of prostate cancer is not well established. We assessed the dependence of [11C]choline maximum standardized uptake values (SUVmax) in the prostate gland on cell malignancy, prostate-specific antigen (PSA) levels, Gleason score, tumour stage and anti-androgenic hormonal therapy. Methods\ \ In this prospective study, PET/CT with [11C]choline was performed in 19 prostate cancer patients who subsequently underwent prostatectomy with histologic sextant analysis (group A) and in six prostate cancer patients before and after anti-androgenic hormonal therapy (bicalutamide 150\ mg/day; median treatment of 4\ months; group B). Results\ \ In group A, based on a sextant analysis with a [11C]choline SUVmax cutoff of 2.5 (as derived from a receiver-operating characteristic analysis), PET/CT showed sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 72, 43, 64, 51 and 60\%, respectively. In the patient-by-patient analysis, no significant correlation was detected between SUVmax and PSA levels, Gleason score or pathological stage. On the contrary, a significant (P \< 0.05) negative correlation was detected between SUVmax and anti-androgenic therapy both in univariate (r 2 = 0.24) and multivariate (r 2 = 0.48) analyses. Prostate [11C]choline uptake after bicalutamide therapy significantly (P \< 0.05) decreased compared to baseline (6.4 ± 4.6 and 11.8 ± 5.3, respectively; group B). Conclusion\ \ PET/CT with [11C]choline is not suitable for the initial diagnosis and local staging of prostate cancer. PET/CT with [11C]choline could be used to monitor the response to anti-androgenic therapy.}, author = {Giovacchini, Giampiero and Picchio, Maria and Coradeschi, Elisa and Scattoni, Vincenzo and Bettinardi, Valentino and Cozzarini, Cesare and Freschi, Massimo and Fazio, Ferruccio and Messa, Cristina}, citeulike-article-id = {2810207}, citeulike-linkout-0 = {http://dx.doi.org/10.1007/s00259-008-0716-2}, day = {14}, doi = {10.1007/s00259-008-0716-2}, journal = {European Journal of Nuclear Medicine and Molecular Imaging}, keywords = {choline, pet, prostate, psa}, month = {June}, number = {6}, pages = {1065--1073}, posted-at = {2008-05-18 17:02:15}, priority = {5}, title = {[11C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy}, url = {http://dx.doi.org/10.1007/s00259-008-0716-2}, volume = {35}, year = {2008} }

TY - JOUR ID - citeulike:2810207 L3 - citeulike-article-id:2810207 N2 - Abstract Purpose  The accuracy of positron emission tomography (PET)/CT with [11C]choline for the detection of prostate cancer is not well established. We assessed the dependence of [11C]choline maximum standardized uptake values (SUVmax) in the prostate gland on cell malignancy, prostate-specific antigen (PSA) levels, Gleason score, tumour stage and anti-androgenic hormonal therapy. Methods  In this prospective study, PET/CT with [11C]choline was performed in 19 prostate cancer patients who subsequently underwent prostatectomy with histologic sextant analysis (group A) and in six prostate cancer patients before and after anti-androgenic hormonal therapy (bicalutamide 150 mg/day; median treatment of 4 months; group B). Results  In group A, based on a sextant analysis with a [11C]choline SUVmax cutoff of 2.5 (as derived from a receiver-operating characteristic analysis), PET/CT showed sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 72, 43, 64, 51 and 60%, respectively. In the patient-by-patient analysis, no significant correlation was detected between SUVmax and PSA levels, Gleason score or pathological stage. On the contrary, a significant (P < 0.05) negative correlation was detected between SUVmax and anti-androgenic therapy both in univariate (r 2 = 0.24) and multivariate (r 2 = 0.48) analyses. Prostate [11C]choline uptake after bicalutamide therapy significantly (P < 0.05) decreased compared to baseline (6.4 ± 4.6 and 11.8 ± 5.3, respectively; group B). Conclusion  PET/CT with [11C]choline is not suitable for the initial diagnosis and local staging of prostate cancer. PET/CT with [11C]choline could be used to monitor the response to anti-androgenic therapy. IS - 6 JF - European Journal of Nuclear Medicine and Molecular Imaging EP - 1073 TI - [11C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy VL - 35 SP - 1065 KW - choline KW - pet KW - prostate KW - psa AU - Giovacchini, Giampiero AU - Picchio, Maria AU - Coradeschi, Elisa AU - Scattoni, Vincenzo AU - Bettinardi, Valentino AU - Cozzarini, Cesare AU - Freschi, Massimo AU - Fazio, Ferruccio AU - Messa, Cristina PY - 2008/06/14/ UR - http://dx.doi.org/10.1007/s00259-008-0716-2 ER -